A randomised controlled trial (RCT) is an experimental study in which participants are allocated to an intervention group or a comparison group purely by chance, so that the only systematic difference between groups is the treatment under test. By combining randomisation, a control or comparison arm and, where possible, blinding, the RCT isolates the effect of an intervention from confounding factors, making it the methodological gold standard for answering causal questions.
The core insight is simple but powerful: if allocation is genuinely random and groups are large enough, known and unknown confounders are distributed evenly across arms. Any difference in outcome can then be attributed to the intervention rather than to pre-existing differences between participants.
Randomisation
Randomisation is the process of assigning participants to groups by chance — for example, by computer-generated sequence. Its purpose is to balance characteristics such as age, severity and unmeasured risk factors across arms, removing selection bias from the comparison. Without it, sicker or healthier participants might cluster in one group, distorting the result.
Allocation concealment
Allocation concealment ensures that those enrolling participants cannot foresee or influence which group a person will join. It is distinct from blinding: concealment protects the randomisation process at the point of assignment, whereas blinding operates after assignment. Poor concealment is one of the most consistently demonstrated sources of exaggerated treatment effects.
Control and comparison
A control or comparison arm provides the counterfactual — what would have happened without the intervention. Comparators may be a placebo, standard care or an active alternative. The placebo arm in particular controls for expectation effects, a topic explored in our article on the placebo and placebo effect.
Blinding
Blinding (or masking) prevents participants, clinicians or assessors from knowing group assignment, reducing conscious and unconscious bias. The mechanics of single, double and triple blinding, and the specific biases they address, are set out in our companion guide to double-blind studies and bias control.
Intention-to-treat analysis
Intention-to-treat (ITT) analysis evaluates participants in the groups to which they were randomised, regardless of whether they completed the assigned treatment. This preserves the benefits of randomisation and gives a realistic estimate of effectiveness in practice, where adherence is imperfect. The contrasting per-protocol analysis, which includes only those who followed the protocol, can reintroduce bias and is usually treated as secondary.
Why the RCT is the gold standard
For causal questions about whether an intervention works, the RCT’s design controls the main threats to validity in one structure. It sits at the heart of the confirmatory stage of drug development, as described in our overview of the pharmaceutical R&D pipeline, and underpins evidence-based decision-making across the research lifecycle.
Anatomy of a well-conducted RCT
A robust trial weaves these elements together rather than relying on any single one. The table below summarises the core components and the threat each addresses.
| Component | Purpose | Threat addressed |
|---|---|---|
| Randomisation | Balance groups by chance | Confounding, selection bias |
| Allocation concealment | Hide upcoming assignment | Manipulation of enrolment |
| Control arm | Provide a counterfactual | Mistaking change for effect |
| Blinding | Conceal group membership | Performance and detection bias |
| Intention-to-treat | Analyse as randomised | Attrition and post-hoc selection |
Power, sample size and pre-specification
Randomisation only balances groups reliably when the sample is large enough, which is why trials specify a target sample size derived from the smallest difference worth detecting. Too small a study may miss a real effect or produce an unstable estimate; an adequately powered one gives the result interpretive weight. Equally important is pre-specifying the primary outcome and analysis plan before the data are seen, so that a single confirmatory test is fixed in advance rather than chosen afterwards. This connects directly to the practice of preregistration and Registered Reports, which protects the trial’s confirmatory status from later analytic flexibility.
Where the RCT sits in the evidence hierarchy
A single trial, however well conducted, is rarely the final word. Findings gain strength when they are replicated and when multiple RCTs are combined in systematic reviews and meta-analyses, which sit above the individual trial in the evidence hierarchy. Conversely, a well-designed observational study can sometimes be more informative than a flawed or under-powered RCT. The design is a powerful tool, not an automatic guarantee of truth, and its value depends on execution and transparent reporting.
Internal versus external validity
Two distinct questions decide whether a trial is useful. Internal validity asks whether the result is true for the participants studied — whether the design genuinely isolated the intervention’s effect from bias and confounding. External validity asks whether that result generalises to other people, settings and conditions. The RCT excels at the first: randomisation, concealment, control and blinding are precisely the tools that secure internal validity. It is weaker on the second, because the controlled conditions and selected participants that protect internal validity can make a trial less representative of routine practice. Strong evidence requires attention to both, and the two sometimes pull in opposite directions.
Pragmatic versus explanatory trials
This tension has produced two broad trial styles. Explanatory trials test whether an intervention can work under ideal, tightly controlled conditions — maximising internal validity and answering questions of efficacy. Pragmatic trials test whether it does work in everyday clinical settings with broader participants and fewer restrictions — favouring external validity and answering questions of effectiveness. Neither is superior in the abstract; the right choice depends on the question being asked. A regulator confirming a causal effect may want an explanatory design, while a health system deciding whether to adopt a treatment may learn more from a pragmatic one. Reporting which style a trial used helps readers interpret how far its findings should travel.
Limits of the design
RCTs are not universally applicable. They can be expensive, may exclude populations seen in routine practice, and are sometimes unethical or impractical — you cannot randomise people to harmful exposures. Tightly controlled conditions can also limit generalisability, the gap between efficacy (does it work in the trial?) and effectiveness (does it work in the real world?). Transparent reporting and good documentation, as encouraged in our guidance for authors, help readers judge how far a trial’s findings extend.
Frequently asked questions
What makes randomisation so important?
Randomisation distributes both known and unknown confounders evenly across groups, so that observed differences in outcome can be attributed to the intervention rather than to pre-existing imbalances.
How is allocation concealment different from blinding?
Allocation concealment hides the upcoming assignment from those enrolling participants, protecting the randomisation itself. Blinding hides group membership after assignment to prevent biased behaviour and assessment.
Why use intention-to-treat analysis?
Analysing participants in their assigned groups preserves randomisation and gives a pragmatic estimate of effect under realistic adherence, avoiding bias introduced by excluding non-completers.
When is an RCT not appropriate?
When randomisation would be unethical, impractical or impossible — for example for harmful exposures or rare conditions — observational designs may be the only feasible option, accepting their greater vulnerability to confounding.
Leave a Reply